Literature DB >> 25712541

The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.

Helen Tedeholm1, Bengt Skoog, Vera Lisovskaja, Björn Runmarker, Olle Nerman, Oluf Andersen.   

Abstract

Interest in the long-term natural history of multiple sclerosis (MS) is being revived, as disability endpoints become increasingly important with the advent of highly efficacious long range but potentially harmful drugs. MS had an increasingly benign course, probably due to better assessment and changing diagnostic criteria. Incidence cohorts reduce inclusion bias, capturing both extreme benign and severe cases. We conducted a 50-year follow-up of an incidence cohort of Gothenburg residents with MS onset in 1950-1964 (n = 254; 212 with an initial relapsing-remitting course and 42 with a monophasic course, diagnostic criteria according to Poser). Patients were followed longitudinally until censoring, death, or study termination in 2012 and evaluated using Kaplan-Meier estimates and Cox regression analysis. Median time to secondary progression was 15 years. Median time to EDSS6 and EDSS7 was 26 and 48 years (n = 254), respectively. The cumulative risk of reaching EDSS6 was 50% at 55 years of age and 80% at 80 years of age (n = 212). A score based on a cluster of clinical features at onset predicted secondary progression, EDSS6, EDSS7, and EDSS10 (hazard ratio 1.6-2.3 per score unit for women, 0.99-1.49 for men). This score predicted the disease course during five decades indirectly, by predicting time to secondary progression. Age at onset predicted the course in men, with 3-6% yearly increase in the risk of reaching disability milestones. The present incidence cohort provided hard outcome data in untreated patients over several decades.

Entities:  

Mesh:

Year:  2015        PMID: 25712541     DOI: 10.1007/s00415-015-7674-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  53 in total

1.  Natural history of multiple sclerosis symptoms.

Authors:  Ilya Kister; Tamar E Bacon; Eric Chamot; Amber R Salter; Gary R Cutter; Jennifer T Kalina; Joseph Herbert
Journal:  Int J MS Care       Date:  2013

2.  Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

Authors:  B Runmarker; O Andersen
Journal:  Brain       Date:  1993-02       Impact factor: 13.501

3.  Clinical studies on multiple sclerosis. I. Presentation of an incidence material from Gothenburg.

Authors:  T Broman; O Andersen; L Bergmann
Journal:  Acta Neurol Scand       Date:  1981-01       Impact factor: 3.209

4.  The evolution of multiple sclerosis epidemiology.

Authors:  L T Kurland
Journal:  Ann Neurol       Date:  1994       Impact factor: 10.422

5.  The natural history of secondary progressive multiple sclerosis.

Authors:  Marcus Koch; Elaine Kingwell; Peter Rieckmann; Helen Tremlett
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-07-16       Impact factor: 10.154

Review 6.  Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis.

Authors:  Sandra Vukusic; Christian Confavreux
Journal:  J Neurol Sci       Date:  2003-02-15       Impact factor: 3.181

7.  Vascular disease among hospitalized multiple sclerosis patients.

Authors:  Norrina B Allen; Judith H Lichtman; Hillel W Cohen; Jing Fang; Lawrence M Brass; Michael H Alderman
Journal:  Neuroepidemiology       Date:  2008-04-25       Impact factor: 3.282

8.  Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG).

Authors:  O Kantarci; A Siva; M Eraksoy; R Karabudak; N Sütlaş; J Ağaoğlu; F Turan; M Ozmenoğlu; E Toğrul; M Demirkiran
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

9.  Physical and social environment and the risk of multiple sclerosis.

Authors:  Melinda Magyari; Nils Koch-Henriksen; Claudia C Pfleger; Per Soelberg Sørensen
Journal:  Mult Scler Relat Disord       Date:  2014-07-21       Impact factor: 4.339

10.  Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy.

Authors:  Orla Tuohy; Lisa Costelloe; Grant Hill-Cawthorne; Ingunn Bjornson; Katharine Harding; Neil Robertson; Karen May; Tom Button; Laura Azzopardi; Onajite Kousin-Ezewu; Michael T Fahey; Joanne Jones; D Alastair S Compston; Alasdair Coles
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-05-21       Impact factor: 10.154

View more
  14 in total

Review 1.  A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.

Authors:  Hernan Inojosa; Undine Proschmann; Katja Akgün; Tjalf Ziemssen
Journal:  J Neurol       Date:  2019-07-30       Impact factor: 4.849

2.  Early predictive factors of disability in CIDP.

Authors:  Emanuele Spina; Antonietta Topa; Rosa Iodice; Stefano Tozza; Lucia Ruggiero; Raffaele Dubbioso; Marcello Esposito; Dario Bruzzese; Lucio Santoro; Fiore Manganelli
Journal:  J Neurol       Date:  2017-08-02       Impact factor: 4.849

3.  The impairment of the functional system and fatigue at the onset of the disease predict reaching disability milestones in relapsing-remitting multiple sclerosis differently in female and male patients.

Authors:  Alina Ivaniuk; Yuliia Solodovnikova; Tetiana Marusich; Anatoliy Son
Journal:  Acta Neurol Belg       Date:  2020-09-30       Impact factor: 2.396

4.  Predicting disease activity in patients with multiple sclerosis: An explainable machine-learning approach in the Mavenclad trials.

Authors:  Sreetama Basu; Alain Munafo; Ali-Frederic Ben-Amor; Sanjeev Roy; Pascal Girard; Nadia Terranova
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-05-09

Review 5.  Definition, prevalence and predictive factors of benign multiple sclerosis.

Authors:  Tatjana Reynders; Miguel D'haeseleer; Jacques De Keyser; Guy Nagels; Marie B D'hooghe
Journal:  eNeurologicalSci       Date:  2017-05-13

6.  Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies.

Authors:  Francisco Coret; Francisco C Pérez-Miralles; Francisco Gascón; Carmen Alcalá; Arantxa Navarré; Ana Bernad; Isabel Boscá; Matilde Escutia; Sara Gil-Perotin; Bonaventura Casanova
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-06-26

Review 7.  Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive Functions.

Authors:  Alessandra Musella; Antonietta Gentile; Francesca Romana Rizzo; Francesca De Vito; Diego Fresegna; Silvia Bullitta; Valentina Vanni; Livia Guadalupi; Mario Stampanoni Bassi; Fabio Buttari; Diego Centonze; Georgia Mandolesi
Journal:  Front Aging Neurosci       Date:  2018-08-08       Impact factor: 5.750

8.  Onset Symptom Clusters in Multiple Sclerosis: Characteristics, Comorbidities, and Risk Factors.

Authors:  Vladeta Ajdacic-Gross; Nina Steinemann; Gábor Horváth; Stephanie Rodgers; Marco Kaufmann; Yanhua Xu; Christian P Kamm; Jürg Kesselring; Zina-Mary Manjaly; Chiara Zecca; Pasquale Calabrese; Milo A Puhan; Viktor von Wyl
Journal:  Front Neurol       Date:  2021-07-06       Impact factor: 4.003

9.  Long-term evolution of multiple sclerosis disability in the treatment era.

Authors:  Bruce A C Cree; Pierre-Antoine Gourraud; Jorge R Oksenberg; Carolyn Bevan; Elizabeth Crabtree-Hartman; Jeffrey M Gelfand; Douglas S Goodin; Jennifer Graves; Ari J Green; Ellen Mowry; Darin T Okuda; Daniel Pelletier; H-Christian von Büdingen; Scott S Zamvil; Alisha Agrawal; Stacy Caillier; Caroline Ciocca; Refujia Gomez; Rachel Kanner; Robin Lincoln; Antoine Lizee; Pamela Qualley; Adam Santaniello; Leena Suleiman; Monica Bucci; Valentina Panara; Nico Papinutto; William A Stern; Alyssa H Zhu; Gary R Cutter; Sergio Baranzini; Roland G Henry; Stephen L Hauser
Journal:  Ann Neurol       Date:  2016-08-13       Impact factor: 10.422

10.  Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.

Authors:  Michaela F George; Farren B S Briggs; Xiaorong Shao; Milena A Gianfrancesco; Ingrid Kockum; Hanne F Harbo; Elisabeth G Celius; Steffan D Bos; Anna Hedström; Ling Shen; Allan Bernstein; Lars Alfredsson; Jan Hillert; Tomas Olsson; Nikolaos A Patsopoulos; Philip L De Jager; Annette B Oturai; Helle B Søndergaard; Finn Sellebjerg; Per S Sorensen; Refujia Gomez; Stacy J Caillier; Bruce A C Cree; Jorge R Oksenberg; Stephen L Hauser; Sandra D'Alfonso; Maurizio A Leone; Filippo Martinelli Boneschi; Melissa Sorosina; Ingrid van der Mei; Bruce V Taylor; Yuan Zhou; Catherine Schaefer; Lisa F Barcellos
Journal:  Neurol Genet       Date:  2016-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.